Michael Gladstone

Mr. Michael Gladstone is an Independent Director at Third Harmonic Bio, Inc., a Partner at Atlas Venture Life Science Advisors LLC, a Partner at Atlas Venture Advisors, Inc. and a Principal at Padlock Therapeutics, Inc. He is on the Board of Directors at Kailera Therapeutics, Inc., Third Harmonic Bio, Inc., Pheon Therapeutics Ltd., Aiolos Bio, Inc., Diagonal Therapeutics, Inc., DOT Therapeutics-2, Inc., Ethyreal Bio, Inc. and Versanis Bio, Inc. Mr. Gladstone was previously employed as an Independent Director by Day One Biopharmaceuticals, Inc., a Principal by Beth Israel Deaconess Medical Center, Inc., a Co-Founder by Q32 Bio Operations, Inc., an Operations Director by Spero Therapeutics, Inc., a Director-Business Operations by Surface Oncology, Inc., and a Senior Associate Consultant by LEK Consulting, Inc. He also served on the board at Akero Therapeutics, Inc., AVROBIO, Inc., Delinia, Inc., IFM Therapeutics LLC, Indalo Therapeutics, Inc., Replimune Group, Inc. and Xilio Therapeutics LLC.
He received his undergraduate degree from Harvard College.